Hepatitis C Serum
Hepatitis C Serum from clinically confirmed HCV donors, frozen within 24 hours. The standard matrix for HCV serology and viral load work: anti-HCV antibody and core antigen immunoassay development, quantitative RNA panels, genotype inclusivity testing, and liver injury and fibrosis markers. Stratification by RNA status, genotype, viraemia, fibrosis stage and DAA treatment, with matched HCV-negative controls.
Human Hepatitis C Serum for Infectious Disease Research
Our Hepatitis C Serum is sourced from IRB-consented donors clinically diagnosed with hepatitis C. Each sample is processed and frozen within 24 hours of collection to keep viral analytes and the surrounding soluble proteome consistent from lot to lot. Serum is acellular and is the standard matrix for HCV serology and viral load testing, so it is supplied for antibody and antigen immunoassay, molecular assay, proteomic and metabolomic work.
Why Hepatitis C Serum for Infectious Disease Research
Hepatitis C is caused by hepatitis C virus, a bloodborne, positive-sense single-stranded RNA flavivirus with pronounced genetic diversity across six major genotypes. Most infections become chronic, and long-term hepatocyte infection with the accompanying immune response drives liver inflammation, progressive fibrosis, cirrhosis and, in a subset of patients, hepatocellular carcinoma. Both the virus and the host response to it circulate.
- Anti-HCV antibody response — antibodies against core, NS3, NS4 and NS5 antigens form the basis of screening immunoassays, and they persist after viral clearance, which is why antibody and RNA results must be interpreted together.
- HCV core antigen and viral RNA — core antigen and quantitative RNA in serum distinguish active infection from resolved infection and underpin viral load and confirmatory testing.
- Genotype diversity — high sequence variability across genotypes and subtypes challenges assay inclusivity, making genotype-annotated donor material valuable for reagent validation.
- Liver injury and fibrosis markers — transaminases, bilirubin, platelet-derived indices and direct fibrosis markers reflect the hepatic consequence of chronic infection.
- Immune response to chronic viral infection — interferon-stimulated mediators and inflammatory cytokines characterise the antiviral response, which is an immune response to infection rather than autoimmunity.
- Post-treatment serology — direct-acting antiviral therapy achieves viral clearance while anti-HCV antibody remains, creating a distinctive serological state that assay developers need real donor material to reproduce.
Donor Stratification Available
- Infection status — anti-HCV-antibody-positive with detectable RNA (active chronic infection), and antibody-positive with undetectable RNA (resolved or treated)
- Genotype — genotype 1 including subtypes 1a and 1b, plus genotypes 2, 3 and others subject to documentation and availability
- Viral load range — high and low viraemia donors, with values reported per lot where captured
- Liver disease stage — donors without significant fibrosis through to documented cirrhosis, where staging is available
- Treatment status — treatment-naive, on direct-acting antiviral therapy, and post-treatment sustained virological response donors; co-infection with HBV or HIV available on request
- Matched healthy controls available, HCV-negative and matched for age, sex and ethnicity
Product Features
- Collected from clinically confirmed hepatitis C donors
- Research Use Only (RUO)
- Processed and frozen within 24 hours of collection
- IRB-approved protocols with documented consent
- Standard and custom aliquot volumes; volumes reported per lot
De-identified Donor Data
- Diagnosis confirmation
- Age, sex assigned at birth, and ethnicity
- Donor-reported allergy and infectious disease history
- Genotype, viral load and treatment context reported per lot where captured
- Additional hepatitis C-specific clinical fields available on request
Applications
- Anti-HCV antibody screening and confirmatory immunoassay development
- HCV core antigen assay development and antigen-antibody combination testing
- Quantitative HCV RNA and viral load assay validation and linearity panels
- Genotyping assay inclusivity and cross-reactivity testing
- Seroconversion and post-treatment serology panel construction
- Liver injury and fibrosis biomarker profiling in chronic viral hepatitis
- Antiviral immune response and cytokine profiling
- Diagnostic reference, calibrator and control material sourcing
Other Hepatitis C Specimen Types
- Hepatitis C Plasma
- Hepatitis C Bulk Plasma
- Hepatitis C PBMC
- Hepatitis C Whole Blood
- Hepatitis C Leukopak
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11-compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
Hepatitis C serum is available in standard and custom volumes. For pricing, international orders or documentation requirements, please email learnmore@sanguinebio.com to ensure compatibility with your country’s regulations. To compare collection formats or check wider availability, visit our human serum page.
Protocols & Documentation
-
Download
Serum Isolation
Protocol for serum preparation from whole blood, including collection handling, clarification, and quality documentation.
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Serum
Frequently Asked Questions
1 Answer
YES – All collections are conducted under IRB-approved protocols and electronic informed consent. Sanguine utilizes Advarra and WCG IRB for oversight.
1 Answer
YES – all our products are research use only (RUO).
1 Answer
You can find our full product catalog here.
1 Answer
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
1 Answer
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
1 Answer
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
1 Answer
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
1 Answer
YES – we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
1 Answer
Each sample from a different individual – Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
1 Answer
YES – Unique donors can be specified and guaranteed based on your requirements.
1 Answer
For information about sample quality, please see: Quality and Compliance
1 Answer
YES – “IRB-approved collection protocols” and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Ask a Question
Need a custom Serum cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.